Applying the Latest Evidence to Guide Treatment of ROS1-Positive Non-Small Cell Lung Cancer

Applying the Latest Evidence to Guide Treatment of ROS1-Positive Non-Small Cell Lung Cancer

New and emerging ROS1-targeted therapies have expanded the treatment options for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). In this bite-sized Booster Quiz, test your knowledge on mechanisms of action of novel ROS1-targeted therapies, and clinical data to guide treatment selection. Receive immediate feedback and, following the quiz, download a summary of key supporting evidence.

  • Provider:PRIME Education, Inc. (PRIME®)
  • Activity Link: https://primeinc.org/online/examining-advances-biomarker-driven-therapies-nsclc-micro-learning-approach
  • Start Date: 2024-08-16 05:00:00
  • End Date: 2024-08-16 05:00:00
  • Credit Details: AAPA Category 1 Credit™️: 0.25 hours
    AMA PRA Category 1 Credit™️: 0.25 hours
    Nursing: 0.25 hours
    Pharmacy: 0.25 hours
  • Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 89750.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner/Team Competence, Learner/Team Performance
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.